Detailed price information for Apogee Therapeutics Inc (APGE-Q) from The Globe and Mail including charting and trades.

RBC Capital analyst Brian Abrahams maintained the stock with a Sector Perform and raised the price target from $688 to $695.

From difficulties swallowing to tummy troubles, thousands of kids face digestive and eating challenges. For many families, the journey to understanding what’s wrong can be long and arduous, often ...